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ABSTRACT 
Porcine circovirus (PCV2)-associated disease is one of the most worrisome diseases affecting the porcine sector, causing 
significant economic losses. Although the currently available vaccines reduce infections and virulence, they are not effective in 
eradicating the virus. In addition, the high rate of mutation of the virus together with the selective pressure exerted by these 
vaccines have favoured the appearance of new strains and changes in the dominant genotype of the virus. Recombinant 
vaccines emerge as a viable alternative to the use of attenuated viruses. However, they are not capable of inducing a potent 
cellular immune response capable of neutralizing the virus. ADL BIONATUR SOLUTIONS is developing recombinant vaccines 
based on the expression of neutralizing epitopes of the PCV2 capsid protein fused to sequences for inducing specific cellular 
immunity. This project has been focused on the production of antigens/candidates for vaccines against PCV2. The antigens 
could be also used to develop technical tools in order to analyze the in vivo efficacy of the vaccines in raising the humoral and 
cellular components of the immune response. 
 
Methods: The production of the antigens was performed in the FLYLIFE platform, based on the use of insect cells as biofactories 
for the production of proteins of interest. The expression of the protein was driven by a baculovirus vector infecting larvae of the 
insect Trichoplusia ni. In addition, a protocol was designed to obtain the antigens under the requirements of concentration and 
purity for immunity tests. 
 
Results: After the expression of the antigens in the larvae of the insect, different conditions of solubilization and purification were 
analyzed, which allowed obtaining the antigens with a 60-78% of purity. Currently, immunity assays are being carried out in mice 
to verify an improvement in the immune response of the vaccine candidate against PCV2. 
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